Harvard Apparatus Regenerative Technology is a biotechnology company developing bioengineered organs in order to better address a collection of life-threatening conditions. The company’s development pipeline is headlined by its proprietary second-generation bioengineered organ implant platform, which is currently being developed as a tool to guide the repair of a patient’s own tissue in three unique indications – including diseases of the trachea, bronchi and esophagus. By utilizing a multi-platform approach to clinical development, HART intends to dramatically expand its market opportunity as it continues to explore the development and regulatory pathways for each indication in the coming months.

In recent months, HART’s scientific efforts have been primarily focused on targeting the body response issues encountered during testing of its first-generation trachea product. The company addressed these concerns by utilizing a more elastic material for the device’s scaffold and changing the type of cell that’s seeded onto the scaffold prior to implementation. Through these modifications, HART anticipates achieving improved regenerative response from the body, as well as a more natural restoration of organ function than was observed from its first-generation product. The company, in partnership with the Mayo Clinic, will put these hypotheses to the test in preclinical studies examining its second-generation platform during the fourth quarter of this year.

“We have made tremendous progress in recent months with the development of our second-generation bioengineered organ implant products,” Jim McGorry, chief executive officer of HART, stated in an August news release. “We are poised to make significant further progress over the coming 18 months, including key preclinical and regulatory achievements.”

As of June 30, the company reported a strong cash balance of $10.1 million with no outstanding debt. This favorable balance sheet is expected to play an instrumental role in HART’s ongoing efforts to develop and commercialize its innovative organ implant platform. In order to streamline this progress, the company has built a dedicated internal team of material scientists, engineers and biologists who, in collaboration with the Mayo Clinic and Connecticut Children’s Medical Center, are focused on bringing its products to the patients who need them as quickly as possible.

Currently, most human organs that are surgically implanted come from donors, creating a debilitating market shortage that costs the lives of an average of 22 people in the United States each day, according to the U.S. Department of Health and Human Services. Additionally, immunosuppression following these transplants – which is necessary to insure that the implanted organ isn’t rejected – can lead to serious, potentially deadly infections. By utilizing a patient’s own cells to produce bioengineered organs, HART’s second-generation platform could effectively address both of these limiting factors, allowing the company to establish a sustainable foothold in some of the medical industry’s most critically underserved indications in the near future.

For more information, visit www.harvardapparatusregen.com

Stellar Biotechnologies, a leading provider of keyhole limpet hemocyanin (KLH) protein, has made considerable progress toward expanding its production capacity in recent months in order to better accommodate increasing demand for the vital nutrient in the pharmaceutical and biotechnology industries. In July, through a collaboration agreement with Ostiones Guerrero SA de CV, the company secured exclusive rights to the development of a second KLH production site in Baja California, Mexico, effectively bolstering its position as a leader in the sustainable manufacture of the valuable ocean resource. Following this partnership, Stellar’s experienced management team was vocal about the positive implications of establishing itself as the only company with a reliable and scalable supply of KLH.

“We expect demand for reliable sources of KLH to grow, both from our existing partners and the broader biotech industry, as the clinical use of novel immunotherapies increases,” Frank Oates, president and chief executive officer of Stellar, stated in a news release. “We believe this [Ostiones] collaboration will better position Stellar to accelerate its production strategy to accommodate the anticipated growth in the industry.”

Earlier this week, Stellar’s strategy was reaffirmed when its partner, Neovacs, presented promising extended follow-up data from its phase I/IIa clinical trial of IFNα-Kinoid, which is being evaluated for the treatment of systemic lupus erythematosus. Because the company’s KLH protein serves as the carrier molecule in Neovacs’s proprietary immunotherapy technology, these results are anticipated to play a key role in increasing the market demand for Stellar’s sustainable supply of the immune-stimulating protein in the future. In preparation for this increase, the company recently entered into an expanded supply agreement to meet Neovacs’s clinical and commercial requirements moving forward.

“This is an important milestone for Neovacs which, we believe, reinforces the role of KLH as a key carrier molecule in immunotherapy treatments,” continued Oates.

Rising demand for KLH has also had a positive impact on Stellar’s top line results in recent months. During its fiscal quarter ended June 30, the company recorded a 117 percent year-over-year increase in total revenues driven primarily by an increase in product sales resulting from its partners’ continued efforts to advance their respective clinical trials in various underserved therapeutic indications. For prospective shareholders, this performance could foreshadow an opportunity for tremendous growth in the coming months, as Stellar looks to effectively leverage its formidable position as the only company with a reliable and scalable supply of KLH.

For more information, visit www.stellarbiotech.com

Stellar Biotechnologies, a leading provider of keyhole limpet hemocyanin (KLH) protein, has made considerable progress toward expanding its production capacity in recent months in order to better accommodate increasing demand for the vital nutrient in the pharmaceutical and biotechnology industries. In July, through a collaboration agreement with Ostiones Guerrero SA de CV, the company secured exclusive rights to the development of a second KLH production site in Baja California, Mexico, effectively bolstering its position as a leader in the sustainable manufacture of the valuable ocean resource. Following this partnership, Stellar’s experienced management team was vocal about the positive implications of establishing itself as the only company with a reliable and scalable supply of KLH.

“We expect demand for reliable sources of KLH to grow, both from our existing partners and the broader biotech industry, as the clinical use of novel immunotherapies increases,” Frank Oates, president and chief executive officer of Stellar, stated in a news release. “We believe this [Ostiones] collaboration will better position Stellar to accelerate its production strategy to accommodate the anticipated growth in the industry.”

Earlier this week, Stellar’s strategy was reaffirmed when its partner, Neovacs, presented promising extended follow-up data from its phase I/IIa clinical trial of IFNα-Kinoid, which is being evaluated for the treatment of systemic lupus erythematosus. Because the company’s KLH protein serves as the carrier molecule in Neovacs’s proprietary immunotherapy technology, these results are anticipated to play a key role in increasing the market demand for Stellar’s sustainable supply of the immune-stimulating protein in the future. In preparation for this increase, the company recently entered into an expanded supply agreement to meet Neovacs’s clinical and commercial requirements moving forward.

“This is an important milestone for Neovacs which, we believe, reinforces the role of KLH as a key carrier molecule in immunotherapy treatments,” continued Oates.

Rising demand for KLH has also had a positive impact on Stellar’s top line results in recent months. During its fiscal quarter ended June 30, the company recorded a 117 percent year-over-year increase in total revenues driven primarily by an increase in product sales resulting from its partners’ continued efforts to advance their respective clinical trials in various underserved therapeutic indications. For prospective shareholders, this performance could foreshadow an opportunity for tremendous growth in the coming months, as Stellar looks to effectively leverage its formidable position as the only company with a reliable and scalable supply of KLH.

For more information, visit www.stellarbiotech.com

The vital role transfer agents play in today’s increasingly hectic capital markets cannot be overstated. The investment community is reliant on trustworthy, rigorous record keeping by transfer agents when it comes to managing the transfer of securities and providing accurate distinctions regarding specialized transactions such as restricted and freely-tradable shares and proactively preventing unlawful distribution of unregistered securities.

While most transfer agents cater to big companies that have hundreds of thousands of shareholders or more, there are very few specialty shops that have mastered what it takes to fully service SMEs, providing them with the kind of mission-critical, tailored service required to successfully execute tender offers, stock splits, and exchange listing shifts. One of the undisputed masters in this field today is Continental Stock Transfer & Trust, which explicitly caters to companies that have 50,000 or less shareholders, offering round-the-clock access to senior experts and a client-tailored approach.

Continental cultivates strong client relationships, secure in the knowledge that the way to succeed in this arena is to deliver to emerging and midsize clients a full suite of personalized offerings. This key distinction makes Continental Stock Transfer & Trust shine when compared to their competition. From secure 24/7 access to balancing tools such as ControlBook Reporting, a proprietary platform offered to its clients to highly customized extended services, like employee and stock plan administration, dividend reinvestment plans, planning and executing successful annual meetings, EDGAR/XBRL services, or the handling of online material design and distributions.

Because of the specific focus Continental Stock Transfer & Trust has on the emerging markets, the firm has become extremely proficient in IPO fundamentals and thus has a long, successful track record of helping private companies go public. Continental understands the importance of preparing the ground work, such as the assembly of management teams, readying financials for audit, crucial hands-on liaision with the underwriters, and the successful navigation of SEC registration requirements.

A real testament to the company’s storied proficiency in the IPO game is its established reputation as an industry leader in special-purpose acquisition company (SPAC) processing, having handled nearly every SPAC brought to market since 1990 via the same full-spectrum approach that has garnered Continental such accolades for its work in executing IPOs. By providing everything from general transfer, warrant and escrow agent services to distribution of proceeds and tax documents, or the necessary intra depository agent, bank and broker facilitation work, Continental has established itself as the leading provider of SPAC processing.

Look to Continental Stock Transfer & Trust for consistent philosophical dedication to emerging and growth companies.

Look closer by visiting www.continentalstock.com

Cherubim Interests has made advances to solidify its position in the alternative construction industry, real estate development market and controlled environment agriculture sector in recent times. The company has adopted a hybrid business model and inventive market strategy that is uncommon in the real estate and agriculture Industries.

Over the years, Cherubim Interests has strategically identified, developed, managed and invested in single-family, multi-family and mixed-use properties in North America while also dealing with various aspects of real estate development from due diligence, acquisition and planning to construction, renovation and management.

Plus, Cherubim Interests is involved in exploring and engaging in existing and potential opportunities in the controlled environment agriculture sector. The company recently found an entry point into this marketplace by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. With this exclusive license, Cherubim, via its wholly-owned subsidiary, BudCube Cultivation Systems USA, plans to take advantage of the rising demand for grow space that accommodates cannabis and other plant species. How? The company intends to build, install and lease portable, scalable plant cultivation facilities for industrial applications.

Cherubim’s hybrid business model resembles the models used by mini-storage companies who lease secured square footage to individuals and corporations based on need. Under its hybrid format, the company offers two solutions:

1. A single tenant or macro solution
2. A multi-tenant or micro solution

With its single tenant micro solution, Cherubim will enter into an agreement to provide a total cultivation solution to a sole tenant. The company will acquire and develop the land required then deploy a macro solution that meets the square-footage specifications requested by that tenant. On the other hand, with its multi-tenant macro solution, Cherubim Interests will choose a variety of land positions across the U.S. then develop and open a number of hand-picked, secured locations where multiple tenants can lease micro solutions to individuals. Each of these locations will have varying sizes based on market research that relates to their geographical area.

Cherubim’s first step regarding these solutions will be to market test the leasing of units in the legal cannabis industry. In the future though, the company envisions many other practical applications for this technology, especially when considering that severe drought conditions have caused vast food shortages all across the globe.

For more information, visit www.cherubiminterests.com or www.budcube.com

Let us hear your thoughts: Cherubim Interests, Inc. Message Board

Computer and video games have come a long way since the days of arcade classics such as Pac-Man and Frogger, as have those who play them. Widespread adoption of smartphones and other advanced mobile devices has put video games literally at the fingertips of a substantial percentage of the global population. According to a report by Digi-Capital, the gaming industry is expected to surpass $100 billion by 2017, and as much as 60 percent of that revenue is forecast to come from mobile and online gaming.

While industry-leaders such as Electronic Arts (NASDAQ: EA), King (NYSE: KING) and Zynga (NASDAQ: ZNGA) continue to grab market share with original titles costing millions of dollars to develop and market, WRIT Media Group, Inc. (OTCQB: WRIT), through the impending debut of its highly-anticipated Retro Infinity Player gaming software, is strategically positioned to capitalize on this market performance for a fraction of the cost.

When released, the Retro Infinity Player will allow gamers to take a stroll down memory lane without the need to locate old school PCs and gaming consoles. The software will enable gamers to play timeless classics created by legendary video game developers such as Amiga and Atari on a wide variety of modern electronic devices – including mobile phones, tablets, smart TVs and streaming set-top devices. By re-releasing classic video games from the late ‘80s and early ‘90s, WRIT plans to establish a presence in the mobile gaming market while avoiding the risks associated with new game development. Since its licensed titles have already been released, the company has a wealth of market data that should play a key role in helping it determine which games have the highest opportunity for success.

“Retro Infinity’s expertise and niche focus is a key factor in allowing us to bring our Amiga classic titles and other classic brands to these various platforms and to the retro gamer,” Eric Mitchell, president of WRIT, stated in a news release. “We are excited to introduce our best classic titles to both an old and new generation of players.”

Earlier this month, WRIT introduced a crowdfunding campaign designed to raise funds and gauge consumer interest for its upcoming gaming software. As that campaign moves forward, look for the company to continue progressing toward the impending release of the Retro Infinity Player, as well as a selection of classic gaming titles.

For more information about the company, visit www.writmediagroup.com

Let us hear your thoughts: WRIT Media Group, Inc. Message Board

RCI Hospitality Holdings, through its subsidiaries, owns and operates over forty upscale gentlemen’s clubs and restaurants in large markets around the country – including New York City, Miami, Philadelphia, Dallas and Minneapolis. With an unrelenting focus on innovation, the company has created a truly upscale, friendly chain of clubs featuring some of the adult entertainment industry’s most popular and recognizable establishments. This market presence was reaffirmed earlier this month when Tootsie’s Cabaret Miami, the country’s largest adult entertainment complex and a subsidiary of RICK, was named “Overall Gentlemen’s Club of the Year” at the 23rd annual Gentlemen’s Club EXPO in New Orleans.

During its fiscal quarter ending June 30, the company successfully leveraged its established market position in order to achieve strong financial growth. RICK’s total revenues for the period were $35.8 million, which represented a 7.3 percent improvement over the previous year. Among this performance, the company achieved a 200 percent year-over-year increase in sales from its Bombshells restaurant/bar segment, underscoring the effectiveness of its recent acquisition-based growth strategy.

RICK’s management team is led by president and chief executive officer Eric Langan, who has headed the company for more than 15 years. By employing self-motivated managers, adhering to strict cost control, increasing cash flow and promoting maximized shareholder value, Langan has helped transform RICK into a leading consolidator in the expansive gentlemen’s club industry while maintaining a consistent spot on Forbes’s list of America’s 200 Best Small Companies. Moving forward, the company will benefit from his immense leadership experience as it continues to expand into the thriving restaurant industry.

With a full roster of past performers who have eventually joined the illusive ranks of Penthouse Pets and Playboy Playmates, it’s easy to see why RICK has continued to thrive in the adult entertainment market for more than three decades. Look for the company to rely on industry innovation and its experienced management team in order to ensure that its collection of major brands – including Rick’s Cabaret, Vivid Cabaret, Tootsie’s Cabaret, Club Onyx, Jaguars Club, XTC Cabaret and Bombshells – remain fixtures in their respective markets for the foreseeable future.

For more information, visit www.rcihospitality.com

As part of the expansion of its Organic Chewable Juice line, Fresh Promise Foods subsidiary Harvest Soul is exhibiting two new flavors at the Natural Products Expo East 2015 in Baltimore, Maryland, September 17-19, 2015. Berry Banana Fusion and Veggie Beet Fusion are making their debut at the expo, along with original flavors Green Fusion and Tropical Fusion.

Natural Products Expo East is the East Coast’s largest natural, organic and healthy products event, expected to reach record numbers this year, with more than 22,000 attendees and more than 1,800 exhibitors. The event provides Harvest Soul considerable brand and product exposure.

“We’re excited to be at Expo East for the first time and launch our two new chewable juice flavors,” Kevin P. Quirk, Fresh Promise Foods CEO and Harvest Soul president stated in the news release. “We believe kids and adults of all ages will love the taste of both juices and the ingredients have incredible health benefits. One example is beet, which boosts stamina, lowers blood pressure and has anti-cancer properties. I’m also extremely proud that our juices are Non-GMO Project verified, a symbol that tells our consumers that Harvest Soul is committed to only using clean and pure ingredients in our juices.”

Harvest Soul Organic Chewable Juices are a blend of at least 15 fruits and vegetables, along with bits of seeds, nuts and berries to create a flavorful, fiber and protein-packed dose of nutrition. Each Harvest Soul juice is concentrate-free and without added flavors or sugar. Harvest Soul Organic Chewable Juices are sold in 12 ounce bottles. All four flavors, including Berry Banana Fusion, Green Fusion, Tropical Fusion and Veggie Beet Fusion, are available at Whole Foods Market locations and online at www.harvestsoul.com.

What makes Harvest Soul Organic Chewable Juice revolutionary to the juice category is that it promotes chewing, which jump starts digestion. Chewing helps the body break down foods, unlocking beneficial nutrients by releasing enzymes that promote better nutrient absorption. Chewing also helps regulate caloric intake, as it takes more time than drinking, making for a more satisfying experience.

Research has also shown that consumers that predominately rely on fruit and vegetable juices to supply their daily nutrition miss out on the health benefits that come from chewing, as well as forfeit the natural fiber and protein wasted during the juicing process. Harvest Soul Chewable Juices are blended, not pressed, so beneficial fiber is retained.

Visit Harvest Soul throughout the duration of the three-day expo at Booth #8222, and follow the company on Facebook: www.facebook.com/harvestsoul and Twitter: @harvestsoul.

For more information visit www.freshpromisefoods.com

Let us hear your thoughts: Fresh Promise Foods, Inc. Message Board

Adaptive Medias, a content syndication and monetization company leading the industry in programmatic advertising across mobile, video and online display, announced that it will be webcasting its presentation at the Singular Research 10th Annual “Best of the Uncovereds” Conference. John B. Strong, Interim Chief Executive Officer, is scheduled to present today at 2:00 PM PT – 2:30 PM in the Pacific Track.

The link to watch this presentation is http://wsw.com/webcast/sr5/adtm. The webcast will be archived for 90 days following the live presentation. Those who wish to schedule a one-on-one investor meeting with Mr. Strong should contact Max Pashman at Investor Relations Partners at 818-280-6800.

For those unfamiliar with the company, Adaptive Medias is a leading provider of mobile video delivery and monetization solutions for publishers, content producers and advertisers. The company’s comprehensive mobile video technology platform, Media Graph, facilitates the delivery of integrated, engaging video content and impactful ad units across all screens and devices. Adaptive Medias is one of the first companies to offer clients a digital video player built specifically for the mobile world.

For more information, please visit www.adaptivem.com

Let us hear your thoughts: Adaptive Medias, Inc. Message Board

Content Checked Holdings, through its innovative family of smartphone applications, is addressing the 15 million people in the U.S. living with food allergies, as well as the 38 million people suffering from migraines and chronic headaches. With a simple barcode scan, consumers using the ContentChecked, MigraineChecked and SugarChecked apps can research a food item of interest and immediately be alerted to potential conflicts with their specific dietary needs. While the apps were created to suit the requirements of people with strict dietary restrictions, they are becoming increasingly popular with individuals seeking to improve the quality of their diets by eliminating potentially harmful ingredients.

SugarChecked, in particular, is a popular tool for helping health-conscious shoppers avoid products that have been shown to stimulate diabetes, cancer, obesity and related medical conditions. According to a report by the Centers for Disease Control and Prevention, approximately 29 million people in the U.S., or 9.3 percent of the population, have diabetes. Additionally, 86 million adults aged 20 years and older have prediabetes, which means that their blood sugar levels are higher than normal but not yet high enough to be classified as type 2 diabetes. Without intervention, prediabetes is likely to become type 2 diabetes in 10 years or less, according to the Mayo Clinic, but studies have shown that healthy lifestyle changes, including eating a healthier diet, can be effective in preventing further progression. In this respect, the market potential for CNCK’s groundbreaking apps is effectively limitless.

In terms of preventing diabetes, SugarChecked is a powerful tool for those looking to improve their diet. The app identifies four main types of sugar – including added sugars, artificial sweeteners, natural low-calorie sweeteners and sugar alcohols – in order to help consumers decipher often-misleading food labels. If a product doesn’t fit into the user’s specific profile, SugarChecked will reference CNCK’s robust database, which includes hundreds of thousands of products, and suggest healthier alternatives in real time.

“SugarChecked addresses a growing problem while empowering people to make smarter choices about their diet,” Kris Finstad, chief executive officer of ContentChecked, stated in a news release. “With cases of diabetes and obesity on the rise – and a direct negative correlation from the excessive intake of sugar – it’s important that we as consumers fully understand the ingredients that go into our food and bodies and what our families eat.”

The SugarChecked app, as well as ContentChecked and MigraineChecked, is currently available for download on the App Store and Google Play.

For more information, visit www.contentchecked.com or www.sugarchecked.com

Let us hear your thoughts: ContentChecked Holdings Inc. Message Board